CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Pliant Therapeutics, Inc. (PLRX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Pliant Therapeutics, Inc. (PLRX)

Pharmaceutical Preparations · market cap $69M · as of 2026-07-15

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
None scheduled
Pipeline
1
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Pliant Therapeutics (PLRX) is a small-cap pharmaceutical company with 171 employees and a market cap of ~$71M, built around a single clinical-stage asset: PLN-74809, a Phase 2 candidate for Idiopathic Pulmonary Fibrosis (IPF). The company has no revenue, a cash balance of $22.2M, and a runway of approximately 3.5 months, placing it in acute near-term financial distress.
The catalyst path

No upcoming catalysts in our calendar.

Pipeline
AssetPhaseIndication
PLN-74809Phase 2Idiopathic Pulmonary Fibrosis
Price & technical context
3-month
-46.1%
6-month
-49.6%
12-month
-60.5%
52-wk range
$0.62–$1.61
vs 50-day MA
-33.8%
vs 200-day MA
-45.0%
Realized vol
48.4%
Max drawdown
-96.1%

Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for PLRX (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.